| scholarly article | Q13442814 |
| P50 | author | Maria Grazia Castagna | Q57070009 |
| ESMO Guidelines Working Group | Q98319238 | ||
| P2093 | author name string | F Pacini | |
| G Pentheroudakis | |||
| L Brilli | |||
| P921 | main subject | thyroid cancer | Q826522 |
| P304 | page(s) | v214-9 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| P478 | volume | 21 Suppl 5 |
| Q91975089 | Association of the Cumulative Dose of Radioactive Iodine Therapy With Overall Survival in Patients With Differentiated Thyroid Cancer and Pulmonary Metastases |
| Q52886445 | Bilateral subtotal thyroidectomy versus hemithyroidectomy plus subtotal resection (Dunhill procedure) for benign goiter: long-term results of a prospective, randomized study. |
| Q34240844 | Cancer incidence and mortality trends in Australian adolescents and young adults, 1982-2007. |
| Q34839752 | Clinicopathological, Biochemical, and Sonographic Features of Thyroid Nodule Predictive of Malignancy among Adult Filipino Patients in a Tertiary Hospital in the Philippines |
| Q38224994 | Differentiated thyroid cancer-personalized therapies to prevent overtreatment. |
| Q53670330 | Encapsulated papillary thyroid carcinoma: is it a distinctive clinical entity with low-grade malignancy? |
| Q53308051 | Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. |
| Q36864736 | Evolving approaches to patients with advanced differentiated thyroid cancer |
| Q40661127 | FNAC and frozen section correlations with definitive histology in thyroid diseases |
| Q37199438 | Fatigue among short- and long-term thyroid cancer survivors: results from the population-based PROFILES registry. |
| Q48651339 | Follicular cell-derived thyroid cancer. |
| Q47371766 | Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer |
| Q48348571 | Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry |
| Q38063535 | High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis |
| Q28548302 | Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation |
| Q37894309 | Molecular nuclear therapies for thyroid carcinoma |
| Q83226168 | One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer |
| Q38222430 | Proteomics, and metabolomics: magnetic resonance spectroscopy for the presurgical screening of thyroid nodules. |
| Q26796901 | RAS proto-oncogene in medullary thyroid carcinoma |
| Q47164528 | Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity. |
| Q37913996 | Radioiodine for remnant ablation and therapy of metastatic disease |
| Q38417634 | Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection. |
| Q36445431 | Recurrent spinal metastasis of a sporadic medullary carcinoma of the thyroid after radiation therapy: a case report and review of the literature |
| Q58733117 | Routine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer-Where is the evidence? |
| Q44792509 | Surgical therapy for thyroid gland malignancies |
| Q64927548 | Systems Biology Approaches to Investigate Genetic and Epigenetic Molecular Progression Mechanisms for Identifying Gene Expression Signatures in Papillary Thyroid Cancer. |
| Q89589293 | The Diagnostic Value of Ultrasound in Medullary Thyroid Carcinoma: A Comparison With Computed Tomography |
| Q51112358 | The impact of molecular testing on the surgical management of patients with thyroid nodules. |
| Q45239564 | The relationship between thyroid volume and malignant thyroid disease. |
| Q51120965 | The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level. |
| Q38027799 | The role of nuclear medicine in differentiated thyroid cancer |
| Q38199223 | The surgical treatment of bilateral benign nodular goiter: balancing invasiveness with complications |
| Q38168128 | Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES). |
| Q47684422 | Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1. |
| Q36533635 | Trends of Thyroid Cancer in Israel: 1980-2012. |
| Q34310219 | Update on thyroid cancer treatment |
| Q39051174 | Values of molecular markers in the differential diagnosis of thyroid abnormalities. |
| Q87306405 | Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer |
Search more.